Renal and cardiovascular effects of non-steroidal anti-inflammatories and selective cox 2 inhibitors;Effets rénaux et cardiovasculaires des anti-inflammatoires non stéroïdiens et des coxibs

Presse Medicale

Volumn 33, Issue 7, 2004, Pages 483-489

  Deray, Gilbert ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

CARDIOVASCULAR EFFECT; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; DRUG CONTRAINDICATION; EDEMA; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERKALEMIA; HYPERTENSION; INCIDENCE; KIDNEY FAILURE; KIDNEY FUNCTION; REVIEW; RISK FACTOR; STATISTICAL SIGNIFICANCE; THROMBOEMBOLISM;

EID: 1842842301     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0755-4982(04)98637-X     Document Type: Short Survey

References (54)

1. Lichenstein DR, Syngal S, Wolfe MM. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. The double-edged sword. Arthritis Rheum 1995; 38:5-18.
2. Ray WA, Griffin MR, Avorn J. Evaluating drug after their approval for clinical use. N Engl J Med 1993; 329: 2029-32.
3. Vane JR. Inhibition of prostaglandin synthesis as a mechanisms of action for aspirin-like drugs. Nat New Biol 1971; 231: 232-35.
4. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/ cyclo-oxygenase homologue. J Biol Chem 1991; 266: 12866-72.
5. Smith WL. The eicosanoids and their biochemical mechanisms of action. Biochem J 1989; 259: 315-24.
6. Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol 1991; 31: 588-98.
7. Goldszer RC, Coodley EL, Rosner MJ, Simons WM, Schawtz AB. Hyperkalemia associated with indomethacin. Arch Int Med 1981; 141: 802-4.
8. Murray MD, Brater DC. Renal toxicity of the anti-inflammatory drugs. Am Rev Pharmacol Toxicol 1993; 32: 435-65.
9. Komers R, Anderson S, Epstein M. Renal and cardiovascular effects of selective cyclo-oxygenase-2 inhibitors. Am J Kidney Dis 2001; 38: 1145-57.
10. Whelton A, Schulman G, Wallemark C, et al. Effects of celecoxib and naproxen on renal function in the ederly. Arch Int Med 2000; 160: 1465-70.
11. Catella-lawson F, McAdam B, Morrison BW et al. Effects of specific inhibition of cyclo-oxygenase-2 on sodium balance, hemodynamics and vasoactive eicosanoids. Pharmacol Exp Ther 1998; 289: 735-41.
12. Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M. Renal effects of selective cyclo-oxygenase-2 inhibition on normotensive salt-depleted subjects. Clin Pharmacol Ther 1999; 66: 76-84.
13. Swan SK, Rudy DW, Lasseter Kc et al. Effects of cyclo-oxygenase-2 inhibition on renal function in elderly persons receiving a low salt diet. A randomized controlled trial. Ann Intern Med 2000; 133: 1-9.
14. Feenstra J, Heerdink ER, Grobbee DE, Stricker BH. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure. Arch Intern Med 2002; 162:265-72.
15. Heedink ER, Leufkens HG, Herings RM, Ottervanger JP, Stricker BH, Bakker A. NSAIDs associated with increase risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med 1998; 158: 1108-12.
16. Bombardier C, Laine L, Reicin A et al. for the VIGOR study group. A comparison of upper gastro-intestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000, 343: 1520-8.
17. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000; 284: 1247-55.
18. Cannon GW, Caldwell JR, Holt P et al. Rofecoxib, a specific inhibitor of cyclo-oxygenase 2, with clinical efficacy comparable with that of declofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Arthritis Rheum 2000; 43: 978-87.
19. Simon LS, Weaver AL, Graham DY et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. A randomized controlled trial. JAMA 1999; 282: 1921-8.
20. Emery P, Zeldler H, Kvien TK et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomized double-blind comparison. Lancet 1999; 354: 2106-11.
21. Whelton A, White WB, Fort JG. Blood pressure control and edema rates in older patients with hypertension and osteoarthritis following treatment with Cox-2 specific inhibitors. J Hypertension 2002; 20 (suppl 4): S82.
22. Mc Kenna F, Weaver A, Fiechtner JJ, Bell AE, Fort JG. Cox-2 specific inhibitors in the management of osteoarthritis of the knee: a placebo-controlled randomized, double-blind study. J Clin Rheumatol 2001; 7:151-9.
23. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM, for the SUCCESS VI study group. Cyclo-oxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001; 8: 85-95.
24. Puma JA, Bello AE, Rodriguez JJ, Fort JG. The effects of Cox-2-specific inhibitors on edema and systolic blood pressure in elderly patients with osteoarthritis and treated hypertension: a pooled analysis on 1.902 patients. Am J Hypert 2002; 15, n°4, part 2:118A (abstract).
25. Burke T, Pettitt D, Henderson SC, Von Allman H, Zhao SZ. Risk of heart failure (HF) claims among stable hypertensive patients who used nonsteroidal anti-inflammatory drugs and Cox-2 specific inhibitors in a U.S. insured population. Ann Rheum Dis 2002; 61 (suppl. 1): SAT343.
26. Zhao SZ, Reynolds MW, Lefkowith J, Whelton A, Arellano FM. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib based on the world health organization/uppsala monitoring centre safety database. Clin Ther 2001; 23: 1478-91.
27. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121: 289-300.
28. Johnson HG. NSAIDs and blood pressure clinical importance for older patients. Drugs Agings 1998; 12: 17-27.
29. Allhat Collaborative reseach group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chloratlidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial. (ALLHAT) JAMA 2000; 283: 1967-75.
30. Collins R, Peto R, Mac Mahon S. Blood pressure, stroke and coronary heart disease. Part 2: short-term reductions in blood pressure: over view of randomized drug trials in their epidemiologic context. Lancet 1990; 335: 827-38.
31. Hypertension diction and follow-up program cooperative group. Effect of stepped care treatment on the incidence of myocardial infarction and angina pectoris: 5-years findings of the hypertension detection and follow-up program. Hypertension 1984; 6: 1198-206.
32. Pope JE, Anderson JJ, Felson DT. A meta-analysis on the effect of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Me 1993; 153: 477-84.
33. Avanzini F, Palumbo G, Alli C et al. on behalf of the collaborative group of the primary prevention project (PP)-hypertension study. Effects of low-dose aspirin on clinic and ambulatory blood pressure in treated hypertensive patients. Am J Hypertens 2000; 13: 611-16.
34. Frishman WH. Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema. Am J Cardiol 2002; 89 (suppl. 1): 18D-25D.
35. Morgan TO, Anderson A, Bertram D. Effect of indomethacin on blood pressure in ederly people with essential hypertension well controlled on amlodipine or enalapril. Am J Hypertens 2000; 13: 1161-7.
36. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? Ann Intern Med 1994; 121: 289-300.
37. Conlin PR, Moore TJ, Swartz SL et al. Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients. Hypertension 2000; 36: 461.
38. Gurwitz JH, Avorn J, Bohn RL, Glynn RJ, Morane M, Mogun H. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA 1994; 272: 781-6.
39. White WB, Kent J, Taylor A, Verburg KM, Lefkowith JB, Whelton A. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 2002; 39: 929.
40. White W, Whelton A, Bello A, Puma J. Rofecoxib but non celecoxib increases systolic blood pressure in hypertensive patients treated with ACE inhibitors and beta-bockers. Ann Rheum Dis 2002; 61 (suppl. 1): THU 247.
41. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective Cox2 inhibitors. JAMA 2001; 286: 954-9.
42. White WB, Faich G, Whelton A et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclo-oxygenase-2 specific inhibitor, versus ibuprofen of diclofenac. Am J Cardiol 2002; 89: 425-30.
43. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002; 359: 118-23.
44. Solomon DH, Glynn RJ, Levin R, Avorn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002; 162: 1099-104.
45. Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002; 162: 1105-10.
46. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 2002; 162: 1111-15.
47. Ray WA, Stein M, Daugherty JR, Hall K, Arbogast PG, Griffin MR. Cox-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360:1071-3.
48. Catela-Lawson F, Reilly MP, Kapoor SC et al. Cyclo-oxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-17.
49. Wilner KD, Rushing M, Walden C et al. Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers. J Clin Pharmacol 2002; 42: 1027-30.
50. Bing RJ, Lomnicka M. Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events ? J Am College Cardiol 2002; 39: 521-22.
51. Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schrör K. Cyclo-oxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999; 353: 9156.
52. Vane JR, Bakhle YS, Botting RM. Cyclo-oxygenase 1 and 2. Ann Rev Pharmacol Toxicol 1998; 38: 97-120.
53. Halushka MK, Halushka PV. Why are some individuals resistant to the cardioprotective effects of aspirin ? Could it be thromboxane A2? Circulation 2002; 105: 1620-2.
54. Cipollone F, Prontera C, Pini B et al. Overexpression of functionally coupled cyclo-oxygenase-2 and prostaglandin E synthasein symptomatic atherosclerotic plaques as a basis of prostaglandin E2-dependent plaque instability. Circulation 2001; 104: 921-7.